{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:51:29Z","timestamp":1792601489084,"version":"4.5.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Peripheral T-cell lymphomas (PTCL) are a rare, heterogeneous subset of non-Hodgkin lymphomas (NHL) that are biologically and clinically distinct from B-cell lymphomas. They are typically resistant to chemotherapy and associated with poor outcomes compared to most B-cell malignancies. Despite this, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like regimens remain the standard frontline therapy, even though pivotal studies establishing CHOP in NHL included only B-cell patients, with no evidence for PTCL. For decades, efforts to improve outcomes have focused on \u201cCHOP-plus\u201d strategies, adding novel agents to the backbone. Outside of anaplastic large cell lymphoma, in which brentuximab vedotin has improved survival, this approach has generally failed; in most PTCL subtypes, 5-drug regimens add toxicity without clear benefit. After 2 decades of disappointing results, this review critically examines the evidence, the limitations of current strategies, and opportunities to rethink future approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018042","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:58:02Z","timestamp":1770839882000},"page":"3867-3877","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Are CHOP-plus really CHOP-minus propositions in the treatment of PTCL? A comprehensive assessment of the strategy"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4208-0541","authenticated-orcid":false,"given":"Nazaneen D.","family":"Saleh","sequence":"first","affiliation":[{"name":"1Rush Medical College, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Virginia Comprehensive Cancer Center, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"25","key":"2026060911314848600_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"25","key":"2026060911314848600_bib2","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2026060911314848600_bib3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026060911314848600_bib4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","article-title":"Non-Hodgkin\u2019s lymphomas","volume":"8","author":"Zelenetz","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2026060911314848600_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"issue":"1","key":"2026060911314848600_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo Study Group","volume":"79","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"2026060911314848600_bib7","doi-asserted-by":"crossref","first-page":"863269","DOI":"10.3389\/fonc.2022.863269","article-title":"Epidemiological characteristics of peripheral T-cell lymphoma: a population-based study","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"2026060911314848600_bib8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2026060911314848600_bib9","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10168","key":"2026060911314848600_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2026060911314848600_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"2026060911314848600_bib12","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"2026060911314848600_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026060911314848600_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026060911314848600_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13400","article-title":"Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data","volume":"170","author":"Bates","year":"2015","journal-title":"Br J Haematol"},{"issue":"22","key":"2026060911314848600_bib16","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2026060911314848600_bib17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","article-title":"Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma","volume":"21","author":"Jain","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"32","key":"2026060911314848600_bib19","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO-24-01654","article-title":"Oncology accelerated approval confirmatory trials: when a failed trial is not a failed drug","volume":"42","author":"Mehta","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026060911314848600_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"37","author":"O\u2019Connor","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026060911314848600_bib22","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2026060911314848600_bib23","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"20","key":"2026060911314848600_bib20","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2026060911314848600_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"suppl 5","key":"2026060911314848600_bib24","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d\u2019Amore","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"2026060911314848600_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE Registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"key":"2026060911314848600_bib39","unstructured":"Surveillance, Epidemiology, and End Results Program. National Cancer Institute. Accessed 17 February 2026. https:\/\/seer.cancer.gov\/."},{"issue":"14","key":"2026060911314848600_bib40","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"issue":"11","key":"2026060911314848600_bib26","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1016\/S2352-3026(20)30222-2","article-title":"A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise","volume":"7","author":"Lue","year":"2020","journal-title":"Lancet Haematol"},{"key":"2026060911314848600_bib42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018254","article-title":"Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma","author":"Ruan","year":"16  2023","journal-title":"Blood"},{"issue":"1","key":"2026060911314848600_bib43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bjh.12326","article-title":"Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnoses peripheral T-cell lymphoma","volume":"162","author":"Oki","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"2026060911314848600_bib44","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s10637-013-0015-z","article-title":"A phase I study of everolimus and CHOP in newly diagnoses peripheral T-cell lymphomas","volume":"31","author":"Kim","year":"2013","journal-title":"Invest New Drugs"},{"issue":"6","key":"2026060911314848600_bib45","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","article-title":"A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin difitox and cylophosphamide, doxorubicin, vincristine, and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study","volume":"54","author":"Foss","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2026060911314848600_bib46","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","article-title":"Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"issue":"22","key":"2026060911314848600_bib47","first-page":"8210","article-title":"Chidamide combined with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma","volume":"10","author":"Gui","year":"2021","journal-title":"Cancer Med"},{"key":"2026060911314848600_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T-cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2026060911314848600_bib48","first-page":"739","article-title":"Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial","volume":"8","author":"Iyer","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026060911314848600_bib49","first-page":"21","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"14","author":"Johnston","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026060911314848600_bib27","volume-title":"Romidepsin. Package insert","year":"2009"},{"issue":"16","key":"2026060911314848600_bib28","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2026060911314848600_bib29","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/1535-7163.MCT-20-0377","article-title":"Targeting the T-cell lymphoma epigenome induces cell death, cancer testes antigens, immune-modulatory signaling pathways","volume":"20","author":"Scotto","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"2026060911314848600_bib30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood"},{"issue":"14","key":"2026060911314848600_bib50","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/bloodadvances.2022009445","article-title":"Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma","volume":"7","author":"Kalac","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2026060911314848600_bib31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2026060911314848600_bib34","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","article-title":"Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial","volume":"30","author":"Horwitz","year":"2024","journal-title":"Nat Med"},{"issue":"14","key":"2026060911314848600_bib54","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies","volume":"16","author":"Marchi","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026060911314848600_bib51","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2352-3026(15)00097-6","article-title":"Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial","volume":"2","author":"Tan","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026060911314848600_bib52","first-page":"209","article-title":"Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: results from a phase I\/II open-label multicenter study","volume":"109","author":"Iyer","year":"2024","journal-title":"Haematologica"},{"issue":"26","key":"2026060911314848600_bib35","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1200\/JCO.2005.05.014","article-title":"Targeting histones and proteasomes: new strategies for the treatment of lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026060911314848600_bib36","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1158\/1078-0432.CCR-15-0033","article-title":"Aurora A kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma","volume":"21","author":"Zullo","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2026060911314848600_bib37","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","article-title":"HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL","volume":"118","author":"Kalac","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2026060911314848600_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"2026060911314848600_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","article-title":"The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026060911314848600_bib33","volume-title":"Duvelisib. Package insert","year":"2018"},{"issue":"4","key":"2026060911314848600_bib41","first-page":"282","article-title":"Management of T-cell malignancies: Bench-to-bedside targeting of epigenetic biology","volume":"75","author":"Sabzevari","year":"2025","journal-title":"CA Cancer J Clin"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3867\/2523592\/blooda_adv-2025-018042-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3867\/2523592\/blooda_adv-2025-018042-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:32:01Z","timestamp":1781019121000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/3867\/566565\/Are-CHOP-plus-really-CHOP-minus-propositions-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018042","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,5,28]]}}}